Management of amiodarone-induced thyrotoxicosis

An ageing population with multiple illnesses will increasingly challenge therapeutic skills. Ar-rhythmia, in particular atrial fibrillation (AF), is one of the commonest clinically significant cardiac conditions. The prevalence of AF is estimated at 0.4 % of the general population, increasing with age [2]. It occurs in more than 6 % of those over 80 years of age [3]. Amiodarone is a highly effective agent for the prophylaxis and treatment of many cardiac rhythm disturbances [4]. There is an in-crease in the prevalence of adverse effects due to amiodarone because of its wider use. Side effects of amiodarone include skin photosensitivity, anorexia, nausea, corneal micro-deposits, neuro-logical symptoms (tremors, ataxia, peripheral neu